- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- Extent
-
Online-Ressource, 1 online resource.
- Language
-
Englisch
- Bibliographic citation
-
Echinomycin as a promising therapeutic agent against KSHV-related malignancies ; volume:16 ; number:1 ; day:4 ; month:5 ; year:2023 ; pages:1-6 ; date:12.2023
Journal of hematology & oncology ; 16, Heft 1 (4.5.2023), 1-6, 12.2023
- Creator
-
Chen, Jungang
Lin, Zhen
Song, Jiao
Plaisance-Bonstaff, Karlie
James, Jennifer
Mu, Shengyu
Post, Steven R.
Dai, Lu
Qin, Zhiqiang
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1186/s13045-023-01441-5
- URN
-
urn:nbn:de:101:1-2023090608523528038267
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
14.08.2025, 10:49 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Chen, Jungang
- Lin, Zhen
- Song, Jiao
- Plaisance-Bonstaff, Karlie
- James, Jennifer
- Mu, Shengyu
- Post, Steven R.
- Dai, Lu
- Qin, Zhiqiang
- SpringerLink (Online service)
Other Objects (12)
CAR-engineered NK cells; a promising therapeutic option for treatment of hematological malignancies
Combination of BCL-2 inhibitors and immunotherapy: a promising therapeutic strategy for hematological malignancies
KSHV-mediated ROS induction defines novel therapeutic targets in Kaposi's sarcoma
C60 fullerene as promising therapeutic agent for correcting and preventing skeletal muscle fatigue
A VCP modulator, KUS121, as a promising therapeutic agent for post-traumatic osteoarthritis
Metabolic reprogramming and metabolic sensors in KSHV-induced cancers and KSHV infection
Inflammasome inhibitors: promising therapeutic approaches against cancer
RFX1: a promising therapeutic arsenal against cancer
Therapeutic dendritic cell cancer vaccines in hematologic malignancies
BCL-2 as therapeutic target for hematological malignancies
Ancistrocladinium A induces apoptosis in proteasome inhibitor-resistant multiple myeloma cells: a promising therapeutic agent candidate
Concanavalin A as a promising lectin-based anti-cancer agent: the molecular mechanisms and therapeutic potential
CAR-engineered NK cells; a promising therapeutic option for treatment of hematological malignancies
Combination of BCL-2 inhibitors and immunotherapy: a promising therapeutic strategy for hematological malignancies
KSHV-mediated ROS induction defines novel therapeutic targets in Kaposi's sarcoma
C60 fullerene as promising therapeutic agent for correcting and preventing skeletal muscle fatigue
A VCP modulator, KUS121, as a promising therapeutic agent for post-traumatic osteoarthritis
Metabolic reprogramming and metabolic sensors in KSHV-induced cancers and KSHV infection
Inflammasome inhibitors: promising therapeutic approaches against cancer
RFX1: a promising therapeutic arsenal against cancer
Therapeutic dendritic cell cancer vaccines in hematologic malignancies
BCL-2 as therapeutic target for hematological malignancies
Ancistrocladinium A induces apoptosis in proteasome inhibitor-resistant multiple myeloma cells: a promising therapeutic agent candidate
Concanavalin A as a promising lectin-based anti-cancer agent: the molecular mechanisms and therapeutic potential
CAR-engineered NK cells; a promising therapeutic option for treatment of hematological malignancies
Combination of BCL-2 inhibitors and immunotherapy: a promising therapeutic strategy for hematological malignancies
KSHV-mediated ROS induction defines novel therapeutic targets in Kaposi's sarcoma
C60 fullerene as promising therapeutic agent for correcting and preventing skeletal muscle fatigue
A VCP modulator, KUS121, as a promising therapeutic agent for post-traumatic osteoarthritis
Metabolic reprogramming and metabolic sensors in KSHV-induced cancers and KSHV infection
Inflammasome inhibitors: promising therapeutic approaches against cancer
RFX1: a promising therapeutic arsenal against cancer
Therapeutic dendritic cell cancer vaccines in hematologic malignancies
BCL-2 as therapeutic target for hematological malignancies
Ancistrocladinium A induces apoptosis in proteasome inhibitor-resistant multiple myeloma cells: a promising therapeutic agent candidate